Press
- GBI reports on China’s evolving policies for anti-cancer drugs in 2018
- GBI hosts Q2 2018 pipeline review webinar
- GBI reports on “Current status and future trends in immuno-oncology checkpoint inhibitors in China”
- GBI reviews China’s priority review policy and orphan drug filing trends in webinar
- GBI hosts GQCE policy webinar
- GBI industry seminar 2017: China’s shift to innovation under the microscope
- McKinsey, AstraZeneca speakers cast light on China mHealth solutions at GBI-hosted summit
- GBI REBRANDS WEBSITE “GBI HEALTH” AS PRODUCT OFFERINGS EXPAND
- BIOPHARMA AND BEYOND: GBI LAUNCHES DEVINT FOR MED DEVICE INTELLIGENCE
- GBI BROADENS R&D OFFERINGS WITH METRIX FOR LIFE SCIENCE RESEARCH
